Date Filed | Type | Description |
04/10/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
04/07/2017 |
SC 13G
| CANACCORD GENUITY INC. reports a 3.4% stake in IGENE BIOTECHNOLOGY INC |
01/10/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
03/15/2011 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
11/15/2010 |
10-Q
| Quarterly Report for the period ended September 30, 2010 |
10/21/2010 |
4
| KIMELMAN MICHAEL (Chairman of the Board) has filed a Form 4 on IGENE BIOTECHNOLOGY INC
Txns:
| Sold 8,000,000 shares
@ $0.003, valued at
$24k
|
|
08/13/2010 |
10-Q
| Quarterly Report for the period ended June 30, 2010 |
05/14/2010 |
10-Q
| Quarterly Report for the period ended March 31, 2010 |
03/31/2010 |
10-K
| Annual Report for the period ended December 31, 2009 |
12/01/2009 |
8-K
| Quarterly results |
11/24/2009 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
11/13/2009 |
PRE 14C
| Form PRE 14C - Other preliminary information statements |
11/13/2009 |
10-Q
| Quarterly Report for the period ended September 30, 2009 |
08/14/2009 |
10-Q
| Quarterly Report for the period ended June 30, 2009 |
07/23/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
07/23/2009 |
4
| MONAHAN PATRICK F (Director) has filed a Form 4 on IGENE BIOTECHNOLOGY INC |
07/23/2009 |
4
| WEISEBERGER EDWARD J (CFO) has filed a Form 4 on IGENE BIOTECHNOLOGY INC |
07/23/2009 |
4
| HIU STEPHEN F (President) has filed a Form 4 on IGENE BIOTECHNOLOGY INC |
05/15/2009 |
10-Q
| Quarterly Report for the period ended March 31, 2009 |
04/01/2009 |
NT 10-K
| Form NT 10-K -- Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
03/31/2009 |
10-K
| Annual Report for the period ended December 31, 2008 |
02/27/2009 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
01/21/2009 |
8-K
| Form 8-K - Current report |
01/12/2009 |
SC 13G
| Form SC 13G -- Statement of acquisition of beneficial ownership by individuals |
01/08/2009 |
SC 13D/A
| Form SC 13D/A -- General statement of acquisition of beneficial ownership [amend] |
12/22/2008 |
4
| Kempner James L (10% Owner) has filed a Form 4 on IGENE BIOTECHNOLOGY INC |
12/19/2008 |
4
| MONAHAN PATRICK F (Director) has filed a Form 4 on IGENE BIOTECHNOLOGY INC |
11/03/2008 |
10-Q
| Quarterly Report for the period ended September 30, 2008 |
10/03/2008 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
08/07/2008 |
10-Q
| Quarterly Report for the period ended June 30, 2008 |
05/15/2008 |
10-Q
| Quarterly Report for the period ended March 31, 2008 |
02/07/2008 |
8-K
| Form 8-K -- Current report |
01/22/2008 |
8-K
| Changes in Registrant.s Certifying Accountant |
11/06/2007 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and ...
Docs:
|
"SEPARATION AGREEMENT This Separation Agreement is made and entered into as of the 31st day of October, 2007 by and between Igene Biotechnology, Inc. and Tate & Lyle Fermentation Products Ltd. . RECITALS A. Tate & Lyle and Igene entered into a Joint Venture Agreement on March 19, 2003, as amended, to create Astaxanthin Partners Ltd. and certain ancillary agreements to carry out the purpose of Astaxanthin Partners Ltd. . B. Tate & Lyle and Igene are the sole shareholders of the Company, with Igene owning 6,000 Class B Shares of the Company and Tate & Lyle owning 6,000 Class A Shares of the Company . C. Tate & Lyle and Igene wish to terminate their relationship as joint owners of the Company as set forth herein. AGREEMENT NOW, THEREFORE, in consideration of the foregoing Recitals, and of the ..." |
|
|